Home - Allogene
REDEFINING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T™ PRODUCT PLATFORM INNOVATION Multiplex gene-engineering and gene-editing capabilities Proprietary lymphodepletion platform State-of-the-art manufacturing Opportunity for product optimization SEE OUR PIONEERING PLATFORM >> KEY PROGRAMS Cemacabtagene ansegedleucel (cema-cel): Frontline treatment in LBCL, including diffuse large B-cell lymphoma (DLBCL) ALLO-316: ccRCC ALLO-329: autoimmune disease EXPLORE OUR PIPELINE >> LEADERSHIP A […]
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-02 | 25.412 |
| 2025-03 | 23.6 |
| 2025-04 | 17.743 |
| 2025-05 | 23.315 |
| Source | Traffic Share |
|---|---|
| search | 46.83% |
| direct | 40.65% |
| referrals | 6.55% |
| social | 4.77% |
| paid referrals | 1.06% |
| 0.13% |
| Region | Percentage |
|---|---|
| United States | 81.00% |
| India | 6.08% |
| United Kingdom | 5.51% |
| Germany | 4.91% |
| PK | 1.30% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| allogene | 417 | 4,170 | $4.93 |
| allogene therapeutics | 342 | 3,420 | $5.09 |
| allogene therapeutics contact | 6 | 60 | $0.00 |
| allogene therapeutics ca office | 4 | 40 | $0.00 |
| zachary j. roberts, m.d., ph.d. executive vice president, research & development, chief medical officer | 0 | 0 | $0.00 |